Sign up for updates. Be part of our community.

GlaxoSmithKline in $350 Million Cancer Drug Venture

LONDON – Adaptimmune, a biotechnology company, said on Monday that it had reached a deal that could be worth more than $350 million to develop an early stage cancer drug with the pharmaceutical maker GlaxoSmithKline. Click here to read more.

Media Contact:

Kristen Fitch

Kristen Fitch

Senior Director, Marketing